Brokers meet Biotech – four Aussie companies driving medtech solutions

The Market Herald03-21

Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun. That was the message today as four biotech companies and Life ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2421581046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-21 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2421581046","market":"us","top_or_hot":-1,"title":"Brokers meet Biotech – four Aussie companies driving medtech solutions","media":"The Market Herald","content":"<div>\n<p>Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun.\nThat was the message today as four biotech companies and Life ...</p>\n\n<a href=\"https://themarketonline.com.au/brokers-meet-biotech-four-aussie-companies-driving-medtech-solutions-2024-03-22/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brokers meet Biotech – four Aussie companies driving medtech solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrokers meet Biotech – four Aussie companies driving medtech solutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-21 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/brokers-meet-biotech-four-aussie-companies-driving-medtech-solutions-2024-03-22/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun.\nThat was the message today as four biotech companies and Life ...</p>\n\n<a href=\"https://themarketonline.com.au/brokers-meet-biotech-four-aussie-companies-driving-medtech-solutions-2024-03-22/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://themarketonline.com.au/brokers-meet-biotech-four-aussie-companies-driving-medtech-solutions-2024-03-22/","article_id":"2421581046","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2421581046","pubTimestamp":1711028340,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun.That was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and investors at the Broker Meets Biotech event in Perth.Blinklab is listing on the ASX early next month after raising $7 million with 20 cent shares. There have been eight studies since 2020, and a feasibility study including 280 child subjects, found the Software as a Medical Device had sensitivity for identifying autism spectrum disorder at 85 per cent. The company is working towards US Food and Drug Administration approval by early 2026.Other presenters today included Orthocell  chief operating officer Alex McHenry.Company investors include Chris Ellison of Mineral Resources  and the McCusker Family, and the company has Professor Fiona Wood and Kim Beazley on the Board.Meanwhile, HITIQ  has a smart mouthguard with 15,000 data points to measure the force","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","OCC.AU":"ORTHOCELL LTD","BK7507":"资源股","MIN.AU":"MINERAL RESOURCES LTD","BK7508":"医药生物股","EX1.AU":"EXOPHARM LTD","HIQ.AU":"Hitiq Limited","BK7067":"生物科技","BK7094":"医疗保健技术","BK7504":"锂钴概念"},"translate_title":"经纪人会见生物技术——四家澳大利亚公司推动医疗技术解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EX1.AU":1,"HIQ.AU":1,"MIN.AU":1,"OCC.AU":1},"content_text":"Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun.\nThat was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and investors at the Broker Meets Biotech event in Perth.\nIt was hosted by Brian Leedman, a Healthcare sector leader who drove the development of ResApp Health- the company behind smartphone tech that analyses a cough to diagnose respiratory illnesses including pneumonia, asthma and bronchiolitis. That business, which began as a University of Queensland start-up, was acquired by Pfizer in a $179 million deal in 2022.\nMr Leedman is now chair of Blinklab, which has an app to assist in evaluation and diagnosis of conditions including autism and ADHD through measuring blinking rates and neurobehavior – again using a smart-phone. \nBlinklab is listing on the ASX early next month after raising $7 million with 20 cent shares. There have been eight studies since 2020, and a feasibility study including 280 child subjects, found the Software as a Medical Device had sensitivity for identifying autism spectrum disorder at 85 per cent. The company is working towards US Food and Drug Administration approval by early 2026.\nOther presenters today included Orthocell (ASX:OCC) chief operating officer Alex McHenry.\nOrthocell has collagen-based devices for tissue and tendon healing, but now also for repairing peripheral nerve damage caused by injuries.\nCompany investors include Chris Ellison of Mineral Resources (ASX:MIN) and the McCusker Family, and the company has Professor Fiona Wood and Kim Beazley on the Board.\nMeanwhile, HITIQ (ASX:HIQ) has a smart mouthguard with 15,000 data points to measure the forces experienced in the brain during hard impact and concussion. It’s been developed to support the identification, monitoring and management of sport-related brain injuries.\nHITIQ chief commercial officer Damien Hawes discussed the company, which has secured a cornerstone agreement with the AFL. While it’s being adopted across professional contact sports and the military, the company is working to bring the mouthguards and  accompanying subscription-based app, to grassroots players.\nAlso presenting today was Canadian-based clinical-stage psilocin company Tryp Therapeutics which has a Prospectus to raise $6.5 million with 2 cent shares, after being acquired by Exopharm (ASX:EX1).\nTryp MD and CEO Jason Carroll said Tryp was developing an IV infusion of psilocin – a compound from psychedelic mushrooms – to treat pain and anxiety disorders. He said the IV infusion addressed limitations of orally-administered psilocybin used by competitors. It has trialled its treatment for binge eating disorder and is also targeting conditions including anxiety, depression, fibromyalgia and irritable bowel syndrome.\nDisclaimer: The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2421581046"}